
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc is experiencing a positive financial trajectory, with a revised 2025 revenue estimate of $387.3 million, up from $374.0 million, bolstered by the company's robust second-quarter performance and growth in its surgical business segment. The company's reported revenue for the most recent quarter reached $98.6 million, marking a year-over-year increase of approximately 13%, driven by significant contributions from its wound care portfolio and surgical products. Despite a 16% year-over-year rise in selling, general, and administrative expenses to $64.2 million, the strong revenue growth in both the wound care and surgical divisions indicates a favorable outlook for the company's financial health.
Bears say
MiMedx Group Inc has experienced a decline in its gross margin, decreasing from approximately 83% to 81% in the second quarter of 2025, primarily due to production variances and product mix issues. Despite reiterating guidance for low double-digit year-over-year revenue growth and a 20% adjusted EBITDA margin, concerns loom over the volatility in reimbursement rates from CMS, which could adversely affect the company's financial performance. These factors contribute to a general negative outlook on MiMedx Group’s stock, highlighting potential challenges in maintaining profitability and revenue growth.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares